Details for Patent: 7,547,719
✉ Email this page to a colleague
Which drugs does patent 7,547,719 protect, and when does it expire?
Patent 7,547,719 protects PROMACTA KIT and PROMACTA and is included in two NDAs.
Protection for PROMACTA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-two patent family members in twenty-eight countries.
Summary for Patent: 7,547,719
| Title: | 3'-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-y- lidene]hy-drazino]-2'-hydroxy-[1,1'-piphenyl]-acid bis-(monoethanolamine) |
| Abstract: | An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-- ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid. |
| Inventor(s): | Moore; Stephen (Tonbridge, GB) |
| Assignee: | SmithKline Beecham Corp. (Philadelphia, PA) |
| Application Number: | 10/515,304 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,547,719 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Delivery; Process; |
Drugs Protected by US Patent 7,547,719
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-002 | Sep 27, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novartis | PROMACTA KIT | eltrombopag olamine | FOR SUSPENSION;ORAL | 207027-001 | Aug 24, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Novartis | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-001 | Nov 20, 2008 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,547,719
| PCT Information | |||
| PCT Filed | May 21, 2003 | PCT Application Number: | PCT/US03/16255 |
| PCT Publication Date: | December 04, 2003 | PCT Publication Number: | WO03/098992 |
International Family Members for US Patent 7,547,719
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 040083 | ⤷ Try a Trial | |||
| Austria | 452683 | ⤷ Try a Trial | |||
| Australia | 2003241587 | ⤷ Try a Trial | |||
| Brazil | 0310094 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
